Drugs / DR10624
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05378893 | Jun 2022 → Oct 2024 | abdominal obesity-metabolic syndrome | Zhejiang Doer Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07024212 | Apr 2025 → Jun 2026 overdue | metabolic dysfunction-associated steatotic liver disease | Zhejiang Doer Biologics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06555640 | Aug 2024 → Jun 2025 | — | Zhejiang Doer Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07693777 | Aug 2026 → Feb 2029 expected | hypertriglyceridemia | Zhejiang Doer Biologics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07680829 | Aug 2026 → Jun 2030 expected | — | Zhejiang Doer Biologics Co., Ltd. | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07050134 Comparator | Jul 2025 → Dec 2026 expected | atherosclerosis, hypertriglyceridemia | Junbo Ge | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DR10624 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07050134 ↗ |
| Action | Activate | “balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities” NCT05378893 ↗ |
| Modality | Protein / enzyme biologic | “DR10624 is an Fc fusion protein tri-agonist” NCT05378893 ↗ |
| Route | Subcutaneous | “administered via subcutaneous injection” NCT05378893 ↗ |